Selena Lin, Ph.D.

Dr. Lin leads clinical, development, and discovery research operations. Dr. Lin has over a decade of experience in developing PCR-based assays for detecting circulating tumor-related DNA (ctDNA) modifications for cancer diagnostics and monitoring. During her time as VP of Technology Development, she focused on optimizing and robustly implementing numerous HCC biomarkers that are part the JBS HCC test, including a novel biomarker of analyzing HBV DNA integration sites and targeted genes in urine of patients with HBV-related liver disease that is derived from her PhD thesis. Prior to JBS, Dr. Lin was a Molecular Oncology Postdoctoral Research Fellow at John Wayne Cancer Institute. Dr. Lin holds a PhD in Microbiology and Immunology from Drexel University College of Medicine.